about
Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA).Draft Genome Sequences of Clinical Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus Strain APS211 and Its Daptomycin-Susceptible Progenitor APS210Reduced In Vitro Activity of Ceftaroline by Etest among Clonal Complex 239 Methicillin-Resistant Staphylococcus aureus Clinical Strains from AustraliaStenotrophomonas maltophilia: emerging disease patterns and challenges for treatment.Infusional β-lactam antibiotics in febrile neutropenia: has the time come?Stenotrophomonas, Achromobacter, and nonmelioid Burkholderia species: antimicrobial resistance and therapeutic strategies.Herpes simplex virus-2 transmission following solid organ transplantation: Donor-derived infection and transplantation from prior organ recipients.Anaerobes: not to be forgotten in neutropenic fever.A case of subacute sclerosing panencephalitis in a 23-year-old recent immigrant to Australia.Lab on a chip sensor for rapid detection and antibiotic resistance determination of Staphylococcus aureus.Laboratory identification of donor-derived coxsackievirus b3 transmission.Development and management of systemic lupus erythematosus in an HIV-infected man with hepatitis C and B co-infection following interferon therapy: a case report.Erratum to: Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA).Bacteriology and management of necrotizing soft tissue infections.Fosfomycin efficacy and emergence of resistance among Enterobacteriaceae in an in vitro dynamic bladder infection model.Evolution of Daptomycin Resistance in Coagulase-Negative Staphylococci Involves Mutations of the Essential Two-Component Regulator WalKRIn vivo acquisition of fosfomycin resistance in Escherichia coli by fosA transmission from commensal floraOral Fosfomycin Treatment for Enterococcal Urinary Tract Infections in a Dynamic In Vitro ModelImpact of bacterial species and baseline resistance on fosfomycin efficacy in urinary tract infectionsUrinary antibacterial activity of fosfomycin and nitrofurantoin at registered dosages in healthy volunteersOral Fosfomycin Efficacy with Variable Urinary Exposures following Single and Multiple Doses against Enterobacterales: the Importance of Heteroresistance for Growth Outcome
P50
Q26739860-8A73854E-F888-4E7B-8987-09BCD22723B3Q35722282-84D47A1A-F781-4C15-91DD-EAEF5C4D4147Q36290502-8274E4FF-B469-4CEA-A293-B70E1CAAC7FAQ37866819-B1848F99-28DC-4BF9-B027-D6704BBE26ABQ38042306-E73554CD-439A-40E1-A52E-AFCCE914CF9DQ38341051-186C2ED2-7C3E-4DB7-AEB0-B9FBB04539CDQ40158724-ACDB6344-3C15-453D-89FB-1659006BB463Q40326338-5A6B6DF5-E904-4356-9E3F-799F360FE312Q40714514-43644528-97D0-4DE1-A962-A44F8D60E3CCQ40817648-B14F1BF5-0B75-4825-AFEB-C9E3A30B8F17Q41548750-B5844E17-EC5D-4D67-9689-4A20D86D53B5Q41808177-D7BCF432-FC8A-45BE-9AB0-71EF0F4673FEQ42341622-227D76CC-C58C-4C80-AB32-FC3096788B37Q43718729-57541F53-C3F2-44F5-8A93-E8D7701AAF8CQ49667957-7F370ECF-A314-41CC-A9AF-31988715BCF0Q62897611-A5728B7D-DCE6-4029-8F4A-350B497123E7Q90070133-FD500F48-2DEB-4A96-A368-C4B853E66D4FQ91609979-767CA822-ABD8-4E04-944C-A116ACDEA625Q92232322-F728121F-D3BC-4288-AEC3-7BB70D392108Q92418892-11B0EAC6-1094-4A32-B5B1-0BF5E013A7D0Q92452218-5A6FE995-BA74-47C0-A4F4-A4621411D3EF
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Iain J Abbott
@en
Iain J Abbott
@nl
type
label
Iain J Abbott
@en
Iain J Abbott
@nl
prefLabel
Iain J Abbott
@en
Iain J Abbott
@nl
P31
P496
0000-0001-6590-6127